Although prostate cancer is considered an androgen-driven pathology, particularly in the early stages, a number of studies have reported the existence of a cell population with diminished AR activity, and corresponsibly reduced prostate-specific antigen (PSA) expression [21, 65]. The gene discussed is KLK3; the disease is prostate cancer.